Tiềm năng của các prodrug amino acid/dipeptide monoester của Floxuridine trong việc tăng cường khả năng cung cấp thuốc hoạt tính đến các vị trí sâu trong khối u: Nghiên cứu in vitro trên hai lớp tế bào đơn

Bookman MA. Biologic therapies for gynecologic cancer. Curr Opin Oncol. 1995;7:478–84. Gray J, Frith C, Parker J. In vivo enhancement of chemotherapy with static electric or magnetic fields. Bioelectromagnetics. 2000;21:575–83. Kamstock D, Guth A, Elmslie R, Kurzman I, Liggitt D, Coro L, et al. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther. 2006;13:306–17. Keler T, Khan S, Sorof S. Liver fatty acid binding protein and mitogenesis in transfected hepatoma cells. Adv Exp Med Biol. 1997;400A:517–24. Kratz F, Mansour A, Soltau J, Warnecke A, Fichtner I, Unger C, et al. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Arch Pharm (Weinheim). 2005;338:462–72. Kullberg M, Mann K, Owens JL. Improved drug delivery to cancer cells: a method using magnetoliposomes that target epidermal growth factor receptors. Med Hypotheses. 2005;64:468–70. Mittal S, Song X, Vig BS, Landowski CP, Kim I, Hilfinger JM, et al. Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs. Mol Pharm. 2005;2:37–46. Wagner E, Kircheis R, Walker GF. Targeted nucleic acid delivery into tumors: new avenues for cancer therapy. Biomed Pharmacother. 2004;58:152–61. Shimma N, Umeda I, Arasaki M, Murasaki C, Masubuchi K, Kohchi Y, et al. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg Med Chem. 2000;8:1697–706. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274–81. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988;6:1653–64. Grem JL, Harold N, Shapiro J, Bi DQ, Quinn MG, Zentko S, et al. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors. J Clin Oncol. 2000;18:3952–63. Laskin JD, Evans RM, Slocum HK, Burke D, Hakala MT. Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res. 1979;39:383–90. Tsume Y, Hilfinger JM, Amidon GL. Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm. 2008;5:717–27. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13. Barton-Burke M. Gemcitabine: a pharmacologic and clinical overview. Cancer Nurs. 1999;22:176–83. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988;48:4024–31. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs. 1995;6 Suppl 6:7–13. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22:3–10. Tsume Y, Vig BS, Sun J, Landowski CP, Hilfinger JM, Ramachandran C, et al. Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules. 2008;13:1441–54. Landowski CP, Vig BS, Song X, Amidon GL. Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther. 2005;4:659–67. Song X, Lorenzi PL, Landowski CP, Vig BS, Hilfinger JM, Amidon GL. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm. 2005;2:157–67. Behrens I, Kamm W, Dantzig AH, Kissel T. Variation of peptide transporter (PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin. J Pharm Sci. 2004;93:1743–54. Geromichalos GD, Trafalis DT, Katsoulos GA, Papageorgiou A, Dalezis P, Triandafillidis EB, et al. Synergistic interaction between a mixed ligand copper (II) chelate complex and two anticancer agents in T47D human breast cancer cells in vitro. J BUON. 2006;11:469–76. Ohbayashi M, Yasuda M, Kawakami I, Kohyama N, Kobayashi Y, Yamamoto T. Effect of interleukins response to ECM-induced acquisition of drug resistance in MCF-7 cells. Exp Oncol. 2008;30:276–82. Padron JM, van der Wilt CL, Smid K, Smitskamp-Wilms E, Backus HH, Pizao PE, et al. The multilayered postconfluent cell culture as a model for drug screening. Crit Rev Oncol Hematol. 2000;36:141–57. Rubas W, Jezyk N, Grass GM. Mechanism of dextran transport across rabbit intestinal tissue and a human colon cell-line (CACO-2). J Drug Target. 1995;3:15–21. Zhao R, Raub TJ, Sawada GA, Kasper SC, Bacon JA, Bridges AS, et al. Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier. Drug Metab Dispos. 2009;37:1251–8. Au JL, Jang SH, Zheng J, Chen CT, Song S, Hu L, et al. Determinants of drug delivery and transport to solid tumors. J Control Release. 2001;74:31–46. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583–92. Rizvi I, Celli JP, Evans CL, Abu-Yousif AO, Muzikansky A, Pogue BW, et al. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res. 2010;70:9319–28. Ohmori T, Yang JL, Price JO, Arteaga CL. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp Cell Res. 1998;245:350–9. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010;10:241–53. del Carmen MG, Rizvi I, Chang Y, Moor AC, Oliva E, Sherwood M, et al. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst. 2005;97:1516–24. Molpus KL, Kato D, Hamblin MR, Lilge L, Bamberg M, Hasan T. Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res. 1996;56:1075–82. Finlay JC, Mitra S, Patterson MS, Foster TH. Photobleaching kinetics of Photofrin in vivo and in multicell tumour spheroids indicate two simultaneous bleaching mechanisms. Phys Med Biol. 2004;49:4837–60. Friedrich J, Ebner R, Kunz-Schughart LA. Experimental anti-tumor therapy in 3-D: spheroids—old hat or new challenge? Int J Radiat Biol. 2007;83:849–71. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell. 2007;130:601–10. Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, et al. 3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm. 2008;5:849–62. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen. 2004;9:273–85. Kim JB. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol. 2005;15:365–77. Celli JP, Rizvi I, Evans CL, Abu-Yousif AO, Hasan T. Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model. J Biomed Opt. 2010;15:051603. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 2005;5:675–88. Monazzam A, Josephsson R, Blomqvist C, Carlsson J, Langstrom B, Bergstrom M. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer. Breast Cancer Res. 2007;9:R45. Landowski CP, Song X, Lorenzi PL, Hilfinger JM, Amidon GL. Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res. 2005;22:1510–8. Vig BS, Lorenzi PJ, Mittal S, Landowski CP, Shin HC, Mosberg HI, et al. Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res. 2003;20:1381–8. Beauchamp LM, Krenitsky TA. Acyclovir prodrugs: the road to valacyclovir. Drugs Future. 1993;18:619–28. Beauchamp LM, Orr GF, De Miranda P, Burnette TC, Krenitsky TA. Amino acid ester prodrugs of acyclovir. Antiviral Chem Chemother. 1992;3:157–64. Maag H. Ganciclovir pro-drugs: Synthesis and pre-clinical development of valganciclovir (Valcyte™)., AAPS Annual Meeting, Toronto, Canada., 2002. Purifoy DJ, Beauchamp LM, de Miranda P, Ertl P, Lacey S, Roberts G, et al. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J Med Virol. 1993;Suppl 1:139–45. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol. 1999;39:800–4. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000;44:2811–5. Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach FH. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998;246:470–5. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998;15:1154–9. Han HK, Oh DM, Amidon GL. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res. 1998;15:1382–6. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000;89:781–9. Anand BS, Patel J, Mitra AK. Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2. J Pharmacol Exp Ther. 2003;304:781–91. Eriksson AH, Elm PL, Begtrup M, Nielsen R, Steffansen B, Brodin B. hPEPT1 affinity and translocation of selected Gln-Sar and Glu-Sar dipeptide derivatives. Mol Pharm. 2005;2:242–9. Friedrichsen GM, Chen W, Begtrup M, Lee CP, Smith PL, Borchardt RT. Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells. Eur J Pharm Sci. 2002;16:1–13. Meredith D, Temple CS, Guha N, Sword CJ, Boyd CA, Collier ID, et al. Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1. Eur J Biochem. 2000;267:3723–8. Nielsen CU, Andersen R, Brodin B, Frokjaer S, Taub ME, Steffansen B. Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line. J Control Release. 2001;76:129–38. Vabeno J, Lejon T, Nielsen CU, Steffansen B, Chen W, Ouyang H, et al. Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: synthesis and biological investigations. J Med Chem. 2004;47:1060–9. Lorenzi PL, Landowski CP, Song X, Borysko KZ, Breitenbach JM, Kim JS, et al. Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo. J Pharmacol Exp Ther. 2005;314:883–90. Song X, Vig BS, Lorenzi PL, Drach JC, Townsend LB, Amidon GL. Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter. J Med Chem. 2005;48:1274–7. Goolcharran C, Borchardt RT. Kinetics of diketopiperazine formation using model peptides. J Pharm Sci. 1998;87:283–8. Larsen SW, Ankersen M, Larsen C. Kinetics of degradation and oil solubility of ester prodrugs of a model dipeptide (Gly-Phe). Eur J Pharm Sci. 2004;22:399–408.